Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis

Main Article Content

Emma Guttman-Yassky
Stephan Weidinger
Eric Simpson
Melinda Gooderham
Alan Irvine
Lynda Spelman
Jonathan Silverberg
Hany Elmaraghy
Louise DeLuca-Carter
Maria Lucia Buziqui Piruzeli
Chaoran Hu
Fan Emily Yang
Evangeline Pierce
Laia Bardolet
Diamant Thaci


Lebrikuzumab, atopic dermatitis, efficacy, safety


1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

2. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

3. Simpson E, et al. JAMA Dermatol. 2023;159:182-191.

4. Blauvelt et al. Br J Dermatol. 2023;188:740-748

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>